Lumateperone
- Generic Name
- Lumateperone
- Brand Names
- Caplyta
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28FN3O
- CAS Number
- 313368-91-1
- Unique Ingredient Identifier
- 70BSQ12069
- Background
Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects.
...
- Indication
Lumateperone is approved for the treatment of schizophrenia in adults. It is also approved for the treatment of depressive episodes associated with bipolar disorder (i.e. bipolar depression) in adults, as monotherapy and/or adjunctive therapy with lithium or valproate.
- Associated Conditions
- Depressive Episodes, Schizophrenia
- Associated Therapies
- -
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 485
- Registration Number
- NCT04985942
- Locations
- 🇨🇿
Clinical site, Plzen, Czechia
🇸🇰Clinical Site, Zlaté Moravce, Slovakia
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 488
- Registration Number
- NCT04285515
- Locations
- 🇺🇦
Clinical Site, Vinnytsia, Ukraine
🇺🇦Clinical site, Odesa, Ukraine
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 381
- Registration Number
- NCT03249376
- Locations
- 🇺🇦
Clinical Site, Vinnytsia, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.